Precigen (PGEN) Operating Income (2012 - 2026)
Precigen (PGEN) posted quarterly Operating Income of -$6.0 million for Q1 2026, up 73.47% year-over-year from -$3.5 million in Q1 2025, and up 72.33% quarter-over-quarter from -$21.7 million in Q4 2025.
Precigen (PGEN) Operating Income (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Operating Income for 15 consecutive years, with -$6.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 73.47% year-over-year to -$6.0 million; the TTM figure through Mar 2026 stood at -$93.9 million (up 29.51% YoY), while the FY2025 annual figure was -$110.5 million, up 18.16% from the prior year.
- Operating Income improved to -$6.0 million in Q1 2026 per PGEN's latest filing, from -$21.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$6.0 million in Q1 2026 and bottomed at -$60.8 million in Q2 2024.
- Historically, Operating Income has averaged -$25.1 million across 5 years, with a median of -$22.6 million in 2025.
- Annual changes were most pronounced in 2024 — Operating Income plunged 188.07% — and 2026, when it soared 73.47%.
- Precigen's Operating Income stood at -$21.8 million in 2022, then sank by 57.01% to -$34.2 million in 2023, then rose by 16.68% to -$28.5 million in 2024, then advanced by 24.02% to -$21.7 million in 2025, then soared by 72.33% to -$6.0 million in 2026.
- Business Quant data shows PGEN's Operating Income at -$6.0 million in Q1 2026, -$21.7 million in Q4 2025, and -$34.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 22.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.64 Mn |
| Mar 31, 2026 | -5.99 Mn |
| Dec 31, 2025 | -21.67 Mn |
| Sep 30, 2025 | -34.48 Mn |
| Jun 30, 2025 | -31.76 Mn |
| Mar 31, 2025 | -22.60 Mn |
| Dec 31, 2024 | -28.52 Mn |
| Sep 30, 2024 | -21.26 Mn |
| Jun 30, 2024 | -60.84 Mn |
| Mar 31, 2024 | -24.41 Mn |
| Dec 31, 2023 | -34.22 Mn |
| Sep 30, 2023 | -20.94 Mn |
| Jun 30, 2023 | -21.12 Mn |
| Mar 31, 2023 | -23.48 Mn |
| Dec 31, 2022 | -21.80 Mn |
| Sep 30, 2022 | -7.61 Mn |
| Jun 30, 2022 | -24.16 Mn |
| Mar 31, 2022 | -22.15 Mn |
| Dec 31, 2021 | -21.87 Mn |
| Sep 30, 2021 | -21.53 Mn |